Skip to main content

Table 2 Comorbidities and treatments before and after the stabilised IPTW using propensity scores

From: Recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis: a nationwide observational study

Variables All patients Patients after IPTW estimation
mPSL alone group (n = 2602) % rTM group (n = 212) % SMD mPSL alone group (n = 2611) % rTM group (n = 190) % SMD
Comorbidity
 Bronchial asthma 141 5.4 13 6.1 3.1 141 5.4 7 3.7 − 8.2
 Pulmonary emphysema 101 3.9 7 3.3 − 3.1 99 3.8 5 2.6 − 7.1
 Pneumonia 488 18.8 48 22.6 9.6 500 19.1 36 18.9 − 0.4
 Mycotic infection 16 0.6 6 2.8 17.1 22 0.8 2 1.1 0.2
 Pulmonary embolism 14 0.5 0 0 − 10.4 15 0.6 0 0.0 − 10.8
 Bronchiectasis 79 3.0 6 2.8 − 1.2 78 3.0 4 2.1 − 3.8
 Pneumothorax 23 0.9 2 0.9 0.6 23 0.9 1 0.5 − 2.0
 Cor pulmonale 27 1.0 5 2.4 10.2 29 1.1 2 1.1 0.9
 Lung cancer 214 8.2 20 9.4 4.3 218 8.3 13 6.8 − 6.2
 Other types of cancera 187 7.2 12 5.7 − 6.2 184 7.0 10 5.3 − 6.7
 Sepsis 59 2.3 10 4.7 13.4 67 2.6 12 6.3 19.3
 Chronic heart failure 362 13.9 23 10.8 − 9.3 358 13.7 22 11.6 − 6.4
 Tachycardia 186 7.1 12 5.7 − 6.1 183 7.0 11 5.8 − 5.9
 Acute coronary syndrome 171 6.6 11 5.2 − 5.9 167 6.4 4 2.1 − 17.6
 Diabetes mellitus 681 26.2 51 24.1 − 4.9 676 25.9 43 22.6 − 6.9
 Stroke 146 5.6 9 4.2 − 6.3 143 5.5 9 4.7 − 2.7
 Dementia 66 2.5 2 0.9 − 12.2 63 2.4 2 1.1 − 12.0
 Renal failure 272 10.5 27 12.7 7.1 281 10.8 18 9.5 − 4.7
 Liver dysfunction 123 4.7 10 4.7 0 123 4.7 15 7.9 15.9
 Gastroesophageal reflux disease 339 13.0 23 10.8 − 6.7 335 12.8 24 12.6 − 0.8
Treatment within 3 days after hospitalisation
 Noradrenaline 21 0.8 4 1.9 9.4 24 0.9 2 1.1 3.1
 Azithromycin 520 20.0 71 33.5 30.8 547 20.9 34 17.9 − 6.9
 Cyclophosphamide (intravenous) 61 2.3 14 6.6 20.7 72 2.8 7 3.7 4.5
 Cyclosporin 88 3.4 15 7.1 16.6 98 3.8 11 5.8 9.2
 Tacrolimus 27 1.0 18 8.5 35.5 42 1.6 3 1.6 0.2
 Azathioprine 9 0.3 0 0 − 8.3 9 0.3 0 0.0 − 8.2
 Pirfenidone 49 1.9 18 8.5 30.1 62 2.4 4 2.1 − 0.4
 Nintedanib 32 1.2 7 3.3 13.9 35 1.3 4 2.1 4.4
 Sivelestat sodium hydrate 341 13.1 72 34.0 50.6 385 14.7 32 16.8 5.7
 Heparin calcium (intravenous) 52 2.0 0 0 − 20.2 51 2.0 0 0.0 − 19.9
 Dalteparin 20 0.8 1 0.5 − 3.8 19 0.7 0 0.0 − 7.7
 Tranexamic acid 95 3.7 2 0.9 − 18.1 90 3.4 4 2.1 − 8.3
 Haemodialysis 96 3.7 14 6.6 13.2 104 4.0 11 5.8 7.6
 High-flow nasal cannula oxygen therapy 164 6.3 22 10.4 14.8 172 6.6 13 6.8 0.7
 Fresh frozen plasma transfusion 25 1.0 8 3.8 18.5 32 1.2 7 3.7 16.4
 Concentrated platelet transfusion 21 0.8 9 4.2 22.0 28 1.1 3 1.6 3.2
  1. Data were presented as n (%)
  2. IPTW inverse probability of treatment weighting, mPSL methylprednisolone, rTM recombinant human soluble thrombomodulin, SMD standardised mean difference
  3. aDetailed information in Additional file 1: Table S1